Atavistik Bio: Funding, Investors & Team (Sep 2026)
Atavistik Bio is a biotechnology company that specializes in the discovery and development of precision allosteric small molecules aimed at treating metabolic diseases and cancer. The company aims to revolutionize therapeutic approaches by focusing on selective allosteric therapeutics, which can potentially transform treatment options for serious diseases.
Atavistik Bio has raised $160M across 2 funding rounds on record, the most recent a Series B of $40.0M announced in Mar 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Atavistik Bio Company Profile and Key Stats
Latest funding round on record: Mar 2026.
Atavistik Bio Funding Rounds
Atavistik Bio raised $120M in a Series B announced in Dec 2025.
3 months later, a Series B of $40.0M was announced in Mar 2026.
Atavistik Bio Founders and Leadership Team
Contact details for the Atavistik Bio team: 1 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Atavistik Bio Funding Compared to Other Biotechnology Startups
Atavistik Bio's latest round of $40.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Atavistik Bio in Biotechnology and Cambridge
Companies Similar to Atavistik Bio
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Atavistik Bio Funding FAQs
What does Atavistik Bio do?
Atavistik Bio is a biotechnology company that specializes in the discovery and development of precision allosteric small molecules aimed at treating metabolic diseases and cancer. The company aims to revolutionize therapeutic approaches by focusing on selective allosteric therapeutics, which can potentially transform treatment options for serious diseases.
How much funding has Atavistik Bio raised?
Atavistik Bio has raised $160M across 2 rounds on record. The most recent is a Series B of $40.0M announced in Mar 2026.
When did Atavistik Bio last raise funding?
Atavistik Bio's most recent funding round on record is a Series B of $40.0M, announced in Mar 2026.
Who founded Atavistik Bio?
FundedIQ lists Bryan Stuart (Founder), Jared Rutter (Founder) at Atavistik Bio.
Where is Atavistik Bio headquartered?
Atavistik Bio is based in Cambridge, Massachusetts, United States.
How many employees does Atavistik Bio have?
Atavistik Bio is in the 11-50 employee band.
How does Atavistik Bio's funding compare to other Biotechnology startups?
Atavistik Bio's latest round of $40.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Atavistik Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Atavistik Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.